<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01626339</url>
  </required_header>
  <id_info>
    <org_study_id>PPUM/MDU/300/04/03</org_study_id>
    <nct_id>NCT01626339</nct_id>
  </id_info>
  <brief_title>Effect of Intravitreal Anti-VEGF on Retinal Vessels Diameter</brief_title>
  <official_title>Effect of Intravitreal Anti-Vascular Endothelial Growth Factors on Retinal Vessels Diameter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Malaya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Malaya</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who will be scheduled for intravitreal injection of Ranibizumab or Bevacizumab will
      be recruited in this prospective self-controlled trial. Fundus photography will carried out
      at baseline immediately before injection and at 3, 7 days and 30 days after the first
      injection. Using image analysis software, measurements summarized as the central retinal
      artery equivalent (CRAE) and central retinal vein equivalent (CRVE).

      Null Hypothesis: There is no significant difference between arteriolar/venular diameter
      before and after injection of intravitreal ranibizumab/bevacizumab in the treated and
      untreated eye
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal Ranibizumab</intervention_name>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal bevacizumab</intervention_name>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        • Patients who wish and need bevacizumab or ranibizumab treatment for underlying disease

        Exclusion Criteria:

          -  History of previous systemic or ocular Anti-VEGF therapy

          -  History of previous intravitreal injection with any drug

          -  Intraocular pressure ≥ 22

          -  Glaucoma

          -  History or presence of thromboembolic events

          -  Un-controlled blood pressure

          -  Blood donation during the previous 3 weeks

          -  Relevant media opacity of the lens
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mohammadreza Peyman, MD</last_name>
    <phone>0060173387260</phone>
    <phone_ext>1</phone_ext>
    <email>drmpeyman@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Visvaraja Subrayan, Prof</last_name>
    <email>d.visva@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Malaya Medical Center</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammadreza Peyman, MD</last_name>
      <phone>0060173387260</phone>
      <email>drmpeyman@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2012</study_first_submitted>
  <study_first_submitted_qc>June 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2012</study_first_posted>
  <last_update_submitted>June 21, 2012</last_update_submitted>
  <last_update_submitted_qc>June 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anti vascular endothelial growth factor</keyword>
  <keyword>retinal vessels</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
    <mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

